KBC Group NV Has $45.376 Million Position in Jazz Pharmaceuticals plc – (JAZZ)

KBC Group NV raised its position in shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) by 143.1% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 312,661 shares of the specialty pharmaceutical company’s stock after buying an additional 184,046 shares during the period. KBC Group NV owned about 0.52% of Jazz Pharmaceuticals plc – worth $45,376,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of JAZZ. Envestnet Asset Management Inc. boosted its stake in shares of Jazz Pharmaceuticals plc – by 43.0% in the first quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock valued at $141,000 after buying an additional 295 shares in the last quarter. World Asset Management Inc purchased a new stake in shares of Jazz Pharmaceuticals plc – during the first quarter valued at $205,000. Bridges Investment Management Inc. purchased a new stake in shares of Jazz Pharmaceuticals plc – during the first quarter valued at $208,000. Private Advisor Group LLC purchased a new stake in shares of Jazz Pharmaceuticals plc – during the first quarter valued at $215,000. Finally, Mn Services Vermogensbeheer B.V. boosted its stake in shares of Jazz Pharmaceuticals plc – by 2.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 1,601 shares of the specialty pharmaceutical company’s stock valued at $217,000 after buying an additional 44 shares in the last quarter. 88.56% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)

Shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded up 0.01% during trading on Friday, reaching $149.15. 261,766 shares of the company traded hands. Jazz Pharmaceuticals plc – has a 12-month low of $95.80 and a 12-month high of $163.75. The firm has a market capitalization of $8.95 billion, a price-to-earnings ratio of 22.54 and a beta of 1.22. The company has a 50 day moving average price of $153.49 and a 200 day moving average price of $128.98.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $1.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.42 by $0.01. The company had revenue of $376.10 million for the quarter, compared to the consensus estimate of $376.58 million. Jazz Pharmaceuticals plc – had a net margin of 24.81% and a return on equity of 30.50%. The company’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period last year, the firm posted $2.26 earnings per share. On average, equities analysts predict that Jazz Pharmaceuticals plc – will post $11.02 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://transcriptdaily.com/2017/05/20/kbc-group-nv-has-45-376-million-position-in-jazz-pharmaceuticals-plc-jazz.html.

Several analysts have weighed in on the stock. Piper Jaffray Companies set a $181.00 price objective on shares of Jazz Pharmaceuticals plc – and gave the stock a “buy” rating in a research note on Saturday, April 8th. Cowen and Company reaffirmed an “outperform” rating and set a $190.00 price objective on shares of Jazz Pharmaceuticals plc – in a research note on Wednesday, May 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $187.00 price objective on shares of Jazz Pharmaceuticals plc – in a research note on Tuesday, January 24th. Mizuho upped their price objective on shares of Jazz Pharmaceuticals plc – from $127.00 to $152.00 and gave the stock a “buy” rating in a research note on Tuesday, February 21st. Finally, Leerink Swann set a $170.00 price objective on shares of Jazz Pharmaceuticals plc – and gave the stock a “buy” rating in a research note on Wednesday, March 1st. Two equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $183.03.

In related news, CEO Bruce C. Cozadd sold 30,000 shares of Jazz Pharmaceuticals plc – stock in a transaction that occurred on Thursday, May 11th. The shares were sold at an average price of $153.47, for a total transaction of $4,604,100.00. Following the sale, the chief executive officer now directly owns 296,418 shares of the company’s stock, valued at approximately $45,491,270.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals plc – stock in a transaction that occurred on Tuesday, April 11th. The shares were sold at an average price of $152.12, for a total transaction of $152,120.00. Following the sale, the chief executive officer now directly owns 308,491 shares in the company, valued at $46,927,650.92. The disclosure for this sale can be found here. Insiders have sold a total of 50,217 shares of company stock worth $7,709,933 over the last ninety days. 3.90% of the stock is currently owned by insiders.

About Jazz Pharmaceuticals plc –

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

12 Month Chart for NASDAQ:JAZZ

Receive News & Ratings for Jazz Pharmaceuticals plc - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals plc - and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply